Could a seizure drug curb alcohol cravings? new trial investigates
NCT ID NCT05134857
First seen Jul 02, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether zonisamide, a drug currently used for seizures, can help adults with alcohol use disorder drink less. About 205 treatment-seeking participants will receive either zonisamide or a placebo, along with standard support. The study measures alcohol consumption through self-reports and breathalyzer tests over 14 weeks of treatment and follow-up.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- zonisamide
- What this could lead to
- If successful, this could provide a new medication option to help people with alcohol use disorder drink less.
- What could go wrong
- This is a phase 2 trial, so it is still early. The drug may not work better than placebo, and side effects like dizziness or drowsiness are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 205 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Four or more standard drinks on four or more occasions in the prior 30 days. 2. Seeking AUD treatment. 3. Aged 18-65 years. 4. DSM-5 diagnosis of AUD. 5. Ability to read and speak English. 6. Ability to provide written informed consent. 7. Breath alcohol of 0.00 during informed consent. 8. Provision of at least 1 EtG-positive urine test at any time during the induction period. 9. Non-lactating women of childbearing age using reliable form of birth control with a negative urine pregnancy test at baseline, and 10. Attended at least 4 of 6 visits during the induction period. Exclusion Criteria: 1. Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal; 2. Currently receiving any pharmacotherapy for alcohol or in the past 30 days. 3. Current DSM-5 diagnosis of severe substance use disorder other than nicotine. 4. Suicide attempt in the last 20 years. 5. History of hypersensitivity to sulfonamide medication, Stevens-Johnson Syndrome, penicillin allergy or allergic reaction to any drug 6. Systemic autoimmune disease. 7. History of current seizure disorder (e.g., are they receiving medication currently for their seizures, have they ever been told by their provider that they have epilepsy, or do they have a history of recurring seizures in the last 5 years?). 8. Current clinically significant blood dyscrasia. 9. History of clinically significant renal calculi or renal failure; renal compromise (defined by an elevation of serum creatinine above our laboratory's limit of normal). 10. History of traumatic brain injury (TBI; e.g., ever been told by a provider that they had a moderate or severe TBI, lost consciousness for 30 minutes or longer or had a post-traumatic amnesia lasting a day or longer). 11. Any other current, clinically significant physical disease \[i.e., neurologic, renal, rheumatologic, gastrointestinal, hematologic, pulmonary, endocrine, cardiovascular, hepatic, or autoimmune disease\] on the basis of medical history, physical examination, or routine laboratory evaluation that, in the context of the study would represent a risk to the subject, or significant laboratory abnormalities related to hepatic function such as marked elevations of hepatic aminotransferase levels (i.e., AST and ALT) or direct bilirubin, and 12. Any other medical or psychiatric condition that Dr. Rodin determines would compromise safe participation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alcohol use disorder (AUD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington State University
Spokane, Washington, 99202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a 20-Hour infusion break the PTSD-Alcohol cycle?
- PET scans probe Brain's power plants in alcohol use disorder
- Can a bike ride curb drinking and heal the liver?
- Can just seeing and smelling a drink trigger alcohol cravings?
- Can a diabetes drug curb alcohol cravings?
- Can a psychedelic compound help veterans and first responders with PTSD and alcohol use disorder?